Vermont auron

Newton, MA, Aug 10, — Auron Therapeuticsa platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its AI-powered platform, today announced appointments to its vermont auron of directors and management team. Victoria Richon, vermont auron, Ph.

Kate Yen, Ph. Her team identified the differentiation induction mechanism of action that facilitated the clinical development of this novel class of cancer therapies. During her time at Agios, Dr. Prior to joining Agios, Dr. Yen is an author of 47 peer-reviewed publications.

Vermont auron

.

Our goal is to develop life-saving therapies by targeting the altered cell states of cancer, vermont auron, which enable tumor cells to survive, grow and metastasize.

.

Newton, MA, Aug 10, — Auron Therapeutics , a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its AI-powered platform, today announced appointments to its board of directors and management team. Victoria Richon, Ph. Christopher Guiffre, J. We look forward to working together to advance novel drug product candidates identified from our platform that target cancer cell plasticity, a common mechanism that leads to aggressive tumors and resistance to current oncology treatments. Before joining Entact Bio, Dr. Before joining Ribon, Dr.

Vermont auron

Kate Yen, Ph. Her team identified the differentiation induction mechanism of action that facilitated the clinical development of this novel class of cancer therapies. During her time at Agios, Dr. Prior to joining Agios, Dr. Yen is an author of 47 peer-reviewed publications.

Tundra restaurant supply

His laboratory has identified myeloproliferative neoplasm MPN predisposition alleles and characterized somatic genetic and epigenetic alterations in MPN and acute myeloid leukemia AML patients, which has led to new mechanism-based therapies. Her team identified the differentiation induction mechanism of action that facilitated the clinical development of this novel class of cancer therapies. Alexandra joined Polaris Partners in and serves as a partner in the New York office. His major clinical expertise is in development of robust flow cytometry-based assays for assessment of treatment response of hematologic neoplasms. One purpose. Scientific Advisory Board. Previously, she was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she was responsible for the oncology drug discovery and translational medicine portfolio. He earned a B. One purpose. Thomas received his M. Anna earned a D. Su has a Ph. Currently, Dr. Earlier in his career, he was a project leader at Pfizer, focused on targets in respiratory and pain.

Before his death, Auron spent his life as a guardian, and tried to prevent his ward from sacrificing his life. When he died, however, he was taken by Hades and imprisoned in the deepest parts of the Underworld.

Phil from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem iPS cells. Su has a Ph. Antipov performed her postdoctoral research at Harvard Medical School. During her time at Agios, Dr. August 10, Millan began his career at Vertex Pharmaceuticals, working on structure-based approaches to kinase inhibitors for oncology. Vander Heiden received his M. Alexandra performed her undergraduate studies at New York University. Interim Chief Data Officer. He conducts novel Phase 1 clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies and serves as the lead investigator at MSK for the BEAT AML master clinical trial. Her team identified the differentiation induction mechanism of action that facilitated the clinical development of this novel class of cancer therapies. Before joining Auron, Dr. Victoria Richon, Ph. Morrison received his B.